These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719 [TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548 [TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model. Phelps A; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO Vaccine; 2005 May; 23(27):3500-7. PubMed ID: 15855008 [TBL] [Abstract][Full Text] [Related]
30. Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. Rock MT; Yoder SM; Talbot TR; Edwards KM; Crowe JE J Infect Dis; 2004 Apr; 189(8):1401-10. PubMed ID: 15073677 [TBL] [Abstract][Full Text] [Related]
31. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing. Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675 [TBL] [Abstract][Full Text] [Related]
32. [Laboratory markers of vaccinia virus in the vaccinia pulp, glycerinated vaccine and lyophilized suspension stored for 1 to 8 years at -25 degrees C]. Mihancea N Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1981; 26(3):191-7. PubMed ID: 7330566 [No Abstract] [Full Text] [Related]
33. Persistence of cell-mediated immunity to vaccinia virus. Kim SH; Oh MD J Infect Dis; 2007 Sep; 196(5):805-6. PubMed ID: 17674329 [No Abstract] [Full Text] [Related]
34. Contribution to the standardisation of the biological control of anti-smallpox immunoglobulins (antisera). Link F; Majer M Prog Immunobiol Stand; 1970; 4():141-4. PubMed ID: 4098256 [No Abstract] [Full Text] [Related]
35. Identification of vaccinia CD8+ T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Terajima M; Cruz J; Leporati AM; Demkowicz WE; Kennedy JS; Ennis FA Hum Immunol; 2006 Jul; 67(7):512-20. PubMed ID: 16829305 [TBL] [Abstract][Full Text] [Related]
36. Testing the potency of smallpox vaccines, anti-smallpox immune sera and immunoglobulins with the use of own reference vaccine and standard immunoglobulin. Hegedüs L; Szathmáry J; Koller M Ann Immunol Hung; 1972; 16(0):157-61. PubMed ID: 4137964 [No Abstract] [Full Text] [Related]
37. Lack of vaccinia viremia after smallpox vaccination. Cummings JF; Polhemus ME; Hawkes C; Klote M; Ludwig GV; Wortmann G Clin Infect Dis; 2004 Feb; 38(3):456-8. PubMed ID: 14727224 [TBL] [Abstract][Full Text] [Related]
38. [Studies on the effect of Marboran, antivaccine hyperimmune serum and preliminary inoculation with vaccine antigen on intracutaneous vaccination in rabbits]. Käckell MY; Schneweis KE; Spiess H Klin Wochenschr; 1966 Oct; 44(20):1199-204. PubMed ID: 5995160 [No Abstract] [Full Text] [Related]
39. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Wyatt LS; Earl PL; Eller LA; Moss B Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762 [TBL] [Abstract][Full Text] [Related]
40. Prediction of residual immunity to smallpox, by means of an intradermal skin test with inactivated vaccinia virus. Kim SH; Bang JW; Park KH; Park WB; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW J Infect Dis; 2006 Aug; 194(3):377-84. PubMed ID: 16826487 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]